Stocktoria
Entrada Therapeutics, Inc. TRDA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-10-29
Entrada Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -621.1% | 22.3% | -2.5% | — | — |
| Net margin | -565.5% | 31.1% | -5.2% | — | — |
| FCF margin | -509.6% | -21.2% | 104.0% | — | — |
| Return on assets | -38.1% | 12.5% | -1.4% | -37.5% | -16.7% |
| Return on equity | -47.0% | 15.3% | -2.8% | -44.5% | -17.1% |
| Current ratio | 12.53 | 11.15 | 2.33 | 9.55 | 44.46 |
| Revenue growth | -87.9% | 63.4% | — | — | — |
Source: SEC EDGAR filings · CIK 0001689375 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.